<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02846545</url>
  </required_header>
  <id_info>
    <org_study_id>CR108187</org_study_id>
    <secondary_id>CNTO148DML2001</secondary_id>
    <nct_id>NCT02846545</nct_id>
  </id_info>
  <brief_title>A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes</brief_title>
  <acronym>T1GER</acronym>
  <official_title>SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine if golimumab can preserve beta-cell
      function in children and young adults with newly diagnosed Type 1 Diabetes (T1D).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 26, 2016</start_date>
  <completion_date type="Anticipated">January 28, 2021</completion_date>
  <primary_completion_date type="Actual">May 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Double-blind Period: C-peptide Area Under the Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>MMTT-Stimulated 4-Hour C-peptide AUC is the mean area under the C-peptide level time curve over the 4-hour period divided by the duration after a mixed-meal tolerance test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Double-blind Period: Change From Baseline in Insulin use in Units per Kilogram Body Weight per day</measure>
    <time_frame>Baseline to Weeks 26, 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blind Period: Change From Baseline in Glycosylated Haemoglobin (HbA1c)</measure>
    <time_frame>Baseline to Weeks 26, 78 and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blind Period: Hypoglycemic Event Rates</measure>
    <time_frame>Week 0 up to Week 52, Week 52 to Week 104 and Week 0 up to Week 104</time_frame>
    <description>Defined as Blood Glucose Levels(BG) of Less Than or Equal to(=&lt;) 70 Milligram per Deciliter(mg/dL) or Clinical Sequelae in the Absence of a BG Reading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blind Period: C-peptide Area Under the Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) Over Time</measure>
    <time_frame>Baseline to Weeks 26, 78 and 104</time_frame>
    <description>MMTT-Stimulated 4-Hour C-peptide AUC is the mean area under the C-peptide level-time curve over the 4-hour period divided by the duration after a mixed-meal tolerance test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blind Period: Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Week 52 and Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blind Period: Percentage of Participants With Severe Infections Through Weeks 52 and 104</measure>
    <time_frame>Up to Week 52 and Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blind Period: Percentage of Participants With Study Agent Injection Site Reactions Through Week 52</measure>
    <time_frame>Up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-Label Extension Period: Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Week 52 and Week 60</time_frame>
    <description>An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are events between administration of study drug and up to 60 weeks that are absent before treatment or that worsen relative to pre-treatment state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-Label Extension Period: Percentage of Participants with Severe Infections Through Open-Label Weeks 52 and 60</measure>
    <time_frame>Up to Week 52 and Week 60</time_frame>
    <description>Percentage of participants with severe infections (extreme distress, causing significant impairment of functioning or incapacitation, prevents normal everyday activities) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-Label Extension Period: Percentage of Participants with Study Agent Injection Site Reactions Through Week 52</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percentage of participants with study agent injection site reactions (for example, swelling, induration, redness/erythema, pain/tenderness, warmth, bruising or bleeding) will be reported. An injection site reaction is any unfavorable or unintended sign that occurs at the study agent injection site.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Group 1: Golimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous (SC) golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may enter in an open-label (OL) extension period to receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a matching placebo to golimumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.</description>
    <arm_group_label>Group 1: Golimumab</arm_group_label>
    <other_name>SIMPONI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo to golimumab.</description>
    <arm_group_label>Group 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Double-blind Period:

          -  Be positive for at least 1 of the following diabetes-related autoantibodies obtained
             at study screening: Glutamic acid decarboxylase (GAD-65), islet antigen 2 (IA-2), zinc
             transporter 8 (ZnT8), Islet Cell Cytoplasmic Autoantibodies (ICA), or Insulin (if
             obtained within 10 days of the onset of exogenous insulin therapy)

          -  Have a peak stimulated C-peptide level greater than or equal to (&gt;=) 0.2 picomole per
             milliliter (pmol/mL) following a 4-hour Mixed-meal Tolerance Test (MMTT) obtained at
             study screening

          -  Be medically stable on the basis of physical examination, medical history, and vital
             signs performed at screening. If there are abnormalities, they must be consistent with
             the underlying illness in the study population

          -  Females of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin [beta-hCG]) test at screening and a negative urine pregnancy test at the
             Week 0 visit

          -  Participants (or their legally acceptable representatives) are willing and able to
             adhere to requirements, prohibitions, and restrictions specified in this protocol

        Open-Label Extension Period:

        - Participants must meet the responder criteria based on C-peptide area under the
        concentration-time curve (AUC) and insulin dose-adjusted HbA1c (IDAAC) remission score

        Exclusion Criteria:

        Double-blind Period:

          -  Has a history of significant renal, vascular, pulmonary, gastrointestinal, neurologic,
             hematologic, rheumatologic, or psychiatric disease or immune suppression or immune
             deficiency.

          -  Has significant cardiovascular disease, including history of myocardial infarction,
             congestive heart failure, angina, abnormal electrocardiogram or abnormal stress test

          -  Has active infections, is prone to infections or has chronic, recurrent or
             opportunistic infectious disease, including but not limited to, chronic renal
             infection, chronic chest infection (example [eg.], bronchiectasis), sinusitis,
             recurrent urinary tract infection (eg., recurrent pyelonephritis, chronic cystitis),
             Pneumocystis carinii, aspergillosis, latent or active granulomatous infection,
             histoplasmosis, or coccidioidomycosis or an open, draining, or infected non-healing
             skin wound or ulcer

          -  Has a clinically active infection with Epstein-Barr virus (EBV) or an EBV viral load
             &gt;=10,000 copies per milliliter (mL) of plasma obtained at study screening. Has a
             clinically active infection with cytomegalovirus (CMV) or a CMV viral load &gt;= 10,000
             copies per milliliter (mL) of plasma obtained at study screening

          -  Current or prior (within 30 days of screening) treatment that is known to cause a
             significant, ongoing change in the course of T1D or immunologic status, including
             high-dose inhaled, extensive topical, or systemic glucocorticoids

          -  Has another autoimmune disease (eg, rheumatoid arthritis [RA], polyarticular juvenile
             idiopathic arthritis [pJIA], psoriatic arthritis [PsA], ankylosing spondylitis [AS],
             multiple sclerosis [MS], systemic lupus erythematosus [SLE], celiac disease
             [clinically symptomatic and antibody positive, that is, tissue transglutaminase
             Immunoglobulin A [IgA]) excluding clinically stable autoimmune thyroiditis whether
             treated or untreated

          -  Has any of the following tuberculosis [TB] screening criteria: A history of latent or
             active TB prior to screening (including but not limited to a positive QuantiFERON®-TB
             Gold test), signs or symptoms suggestive of active TB upon medical history and/or
             physical examination, recent close contact with a person with known or suspected
             active TB

          -  Has known allergies, intolerance and/or hypersensitivity to human immunoglobulin
             proteins, golimumab or any of its components or its excipients

        Open-Label Extension Period:

          -  Participants having reported clinically significant AEs or serious adverse events
             (SAEs) deemed to be related to the study agent during the double blind period (for
             example. severe infections or hypersensitivity reactions), precluding renewed exposure
             to golimumab

          -  Participants who discontinued study agent administration prior to Week 52 or who have
             completed the Week 104 visit of the double-blind period or discontinued early from
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <disposition_first_submitted>May 19, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>May 19, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 21, 2020</disposition_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

